Inari Medical (NARI) to Release Earnings on Tuesday

Inari Medical (NASDAQ:NARI) is set to announce its earnings results after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Inari Medical has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.15). The firm had revenue of $143.19 million during the quarter, compared to the consensus estimate of $138.32 million. Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. On average, analysts expect Inari Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inari Medical Stock Down 2.5 %

Shares of Inari Medical stock opened at $53.83 on Monday. The firm has a market cap of $3.13 billion, a PE ratio of -131.29 and a beta of 1.01. Inari Medical has a 12-month low of $36.73 and a 12-month high of $71.85. The company’s fifty day simple moving average is $49.94 and its two-hundred day simple moving average is $48.86.

Insider Buying and Selling

In related news, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $50.13, for a total transaction of $3,007,800.00. Following the sale, the director now owns 865,359 shares of the company’s stock, valued at $43,380,446.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Rebecca Chambers sold 964 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $45.39, for a total transaction of $43,755.96. Following the sale, the director now owns 9,944 shares of the company’s stock, valued at $451,358.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $50.13, for a total transaction of $3,007,800.00. Following the sale, the director now directly owns 865,359 shares in the company, valued at approximately $43,380,446.67. The disclosure for this sale can be found here. Insiders have sold 261,293 shares of company stock valued at $13,113,558 over the last quarter. Corporate insiders own 10.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on NARI. Needham & Company LLC lowered shares of Inari Medical from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. Canaccord Genuity Group cut their target price on shares of Inari Medical from $75.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Truist Financial lifted their target price on shares of Inari Medical from $47.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, July 16th. Piper Sandler cut their target price on shares of Inari Medical from $55.00 to $50.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Finally, William Blair assumed coverage on shares of Inari Medical in a research note on Thursday. They set an “outperform” rating on the stock. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.83.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.